Strs Ohio Has $9.42 Million Stock Position in Masimo Corporation $MASI

Strs Ohio boosted its position in shares of Masimo Corporation (NASDAQ:MASI) by 39.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,983 shares of the medical equipment provider’s stock after acquiring an additional 15,848 shares during the period. Strs Ohio owned 0.10% of Masimo worth $9,417,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MASI. Amalgamated Bank lifted its position in shares of Masimo by 5.2% during the 2nd quarter. Amalgamated Bank now owns 21,743 shares of the medical equipment provider’s stock worth $3,658,000 after purchasing an additional 1,081 shares during the last quarter. Retirement Systems of Alabama lifted its holdings in shares of Masimo by 1.7% during the second quarter. Retirement Systems of Alabama now owns 55,003 shares of the medical equipment provider’s stock worth $9,253,000 after buying an additional 916 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Masimo by 5.0% during the second quarter. Assetmark Inc. now owns 1,539 shares of the medical equipment provider’s stock worth $259,000 after buying an additional 73 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Masimo by 26.3% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 471,041 shares of the medical equipment provider’s stock worth $79,239,000 after buying an additional 98,063 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Masimo by 21.6% during the second quarter. Nordea Investment Management AB now owns 31,868 shares of the medical equipment provider’s stock worth $5,330,000 after buying an additional 5,659 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Trading Down 0.6%

Shares of MASI stock opened at $140.65 on Friday. Masimo Corporation has a 52-week low of $133.70 and a 52-week high of $194.88. The stock has a market cap of $7.64 billion, a price-to-earnings ratio of -16.51 and a beta of 1.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. The firm has a fifty day moving average of $144.80 and a 200-day moving average of $154.10.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm had revenue of $617.00 million during the quarter. On average, equities research analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Activity

In related news, Director William R. Jellison bought 3,000 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was acquired at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director owned 4,790 shares in the company, valued at approximately $699,244.20. This represents a 167.60% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 9.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on MASI shares. Piper Sandler upped their target price on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. BTIG Research reiterated a “buy” rating and set a $198.00 target price on shares of Masimo in a research note on Thursday, September 11th. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Finally, Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and a consensus price target of $194.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.